Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.

Publication ,  Journal Article
Alexopoulos, A-S; Andersen, A; Donatsky, AM; Gowda, A; Buse, JB
Published in: Diabetes Obes Metab
August 2021

In the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL (degludec) was superior to insulin glargine 100 units/mL (glargine U100) with respect to the rates of severe (DEVOTE; across trial) and overall symptomatic (SWITCH 2; during the maintenance period of the trial) hypoglycaemia in individuals with type 2 diabetes. In this post hoc analysis, data from 7635 individuals from DEVOTE and 720 individuals from SWITCH 2 were analysed by subgroups of diabetes duration at baseline (<10, ≥10-<15, ≥15-<20 and ≥20 years) using prespecified models from both trials. There was a trend towards lower rates of hypoglycaemia with degludec versus glargine U100 across all diabetes duration subgroups in both trials, with the difference being statistically significant in some subgroups in DEVOTE and SWITCH 2. Overall, however, no significant interaction was observed between diabetes duration and treatment (DEVOTE interaction, P = .496; SWITCH 2 interaction, P = .144). Therefore, in this post hoc analysis of DEVOTE and SWITCH 2, diabetes duration did not appear to affect the reduction in rates of hypoglycaemia observed with degludec compared with glargine U100.

Duke Scholars

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

August 2021

Volume

23

Issue

8

Start / End Page

1983 / 1988

Location

England

Related Subject Headings

  • Insulin, Long-Acting
  • Insulin Glargine
  • Hypoglycemic Agents
  • Hypoglycemia
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alexopoulos, A.-S., Andersen, A., Donatsky, A. M., Gowda, A., & Buse, J. B. (2021). Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. Diabetes Obes Metab, 23(8), 1983–1988. https://doi.org/10.1111/dom.14397
Alexopoulos, Anastasia-Stefania, Andreas Andersen, Anders Meller Donatsky, Amoolya Gowda, and John B. Buse. “Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.Diabetes Obes Metab 23, no. 8 (August 2021): 1983–88. https://doi.org/10.1111/dom.14397.
Alexopoulos A-S, Andersen A, Donatsky AM, Gowda A, Buse JB. Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. Diabetes Obes Metab. 2021 Aug;23(8):1983–8.
Alexopoulos, Anastasia-Stefania, et al. “Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.Diabetes Obes Metab, vol. 23, no. 8, Aug. 2021, pp. 1983–88. Pubmed, doi:10.1111/dom.14397.
Alexopoulos A-S, Andersen A, Donatsky AM, Gowda A, Buse JB. Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. Diabetes Obes Metab. 2021 Aug;23(8):1983–1988.
Journal cover image

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

August 2021

Volume

23

Issue

8

Start / End Page

1983 / 1988

Location

England

Related Subject Headings

  • Insulin, Long-Acting
  • Insulin Glargine
  • Hypoglycemic Agents
  • Hypoglycemia
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • 1103 Clinical Sciences